BGI Genomics Co., Ltd. (300676.SZ) provides genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers, and other organizations in China and internationally; offers DNA, RNA, customized sequencing solutions, and mass spectrometry services; delivers solutions for basic research in human, plant, animal, and microbial species, clinical research in human health, genetic testing and screening, drug discovery and development, agriculture, and biodiversity preservation; provides diagnostics and precision medicines for COVID-19, infectious diseases, and oncology, including COVID-19 PCR test kits and lab solutions; supplies reproductive health basic research and clinical application services, cancer and chronic disease prevention and translational medicine services, infection prevention and control services, multi-omics big data services, and comprehensive precision medical testing solutions. BGI Genomics operates as a subsidiary of BGI Group, founded in 1999 and headquartered in Shenzhen, China, with geographic operations spanning over 100 countries including Europe, North America, Asia-Pacific, and emerging markets in Asia and Africa. The company launched a new line of next-generation sequencing products in 2023, acquired a biotechnology firm specializing in AI-driven diagnostics in January 2023, formed strategic partnerships with pharmaceutical companies for drug discovery integration, and continues international expansion with new branches and multi-omics sequencing centers.